Efficiently develop product candidates in established areas of significant clinical need. We are focused on the development of best-in-class product candidates with differentiated profiles, meaning improved safety and/or efficacy relative to current standards of care. Our intention is to develop our products for ultimate commercialization by us, our partners or licensees after they have received approval from the U.S. Food and Drug Administration, or FDA, and/or other regulatory agencies

SUMMARY OF ATHERSYS, INC.
2011 CASH BONUS INCENTIVE PLAN

On March 25, 2011, the Board of Directors of Athersys, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board of Directors of the Company, approved a cash bonus incentive plan (the “Plan”) for the year ended December 31, 2011 for the named executive officers of the Company. The Plan provides that each participant is eligible to earn a bonus during the award term of January 1, 2011 through December 31, 2011. The Plan provides for the following target bonus percentages of the named executive officer’s salary during the award term, weighted as set forth below on the achievement of specified corporate goals, with the remainder based on individual/functional performance. The corporate goals include advancing the Company’s clinical programs for MultiStem, executing against the established operating plan and capital acquisition objectives, and advancement of strategic partnership and program activities. There is no formally adopted plan document for the Plan.

		Target				Weighting on
Title		Bonus				Corporate Goals
Chief Executive Officer			40	%			100	%
President & Chief Operating Officer			33	%			80	%
Executive Vice President & Chief Scientific Officer			33	%			80	%
Sr. Vice President, Regenerative Medicine			30	%			60	%
Vice President of Finance			25	%			60	%